\-\ Texto\\:\\ \ \(0\)\
\-\ csf\\ positive\\ for\\ ms\ \(0\)\
\-\ steroids\\ only\\.\ \(0\)\
\-\ \\â\\€\\¢\\ mr\\:\\ lesion\\ left\\ middle\\ cerebral\\ peduncle\\ which\\ has\\ low\\ signal\\ on\\ t1\\ and\\ elevated\\ signal\\ on\\ t2\\ mr\ \(0\)\
\-\ \\â\\€\\¢\\ me\\+gd\\:\\ lesion\\ left\\ middle\\ cerebellar\\ peduncle\\ enhances\\.\ \(0\)\
\-\ acute\\ multiple\\ sclerosis\\ \\-\\ enhancing\\ lesion\\ with\\ mass\\ effect\\.\ \(0\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ lymphoma\ \(373\)\
\-\ infarction\ \(233\)\
\-\ 65\\ year\\ old\\ man\\ with\\ history\\ of\\ left\\ thalamic\\ infarct\\.\ \(1\)\
\-\ now\\ presents\\ with\\ new\\ onset\\ of\\ left\\ sided\\ facial\\ pain\\ and\\ numbness\ \(0\)\
\-\ repeat\\ mri\\ 2\\ weeks\\ after\\ steroid\\ treatment\\ revealed\\ almost\\ complete\\ resolution\\ of\\ the\\ lesion\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ peduncle\\:\\ 0\\.1422609387455842\ \(0\)\
\-\ me\\+gd\\:\\ 0\\.09905076880861234\ \(0\)\
\-\ lesion\\:\\ 0\\.07822720116855976\ \(0\)\
\-\ middle\\:\\ 0\\.07022829145263905\ \(0\)\
\-\ thalamic\\:\\ 0\\.0665746816412397\ \(0\)\
\-\ mr\\:\\ 0\\.06101571847070638\ \(0\)\
\-\ ms\\:\\ 0\\.05131486721255212\ \(0\)\
\-\ steroid\\:\\ 0\\.050690486862498066\ \(0\)\
\-\ signal\\:\\ 0\\.05063088382635458\ \(0\)\
\-\ 65\\:\\ 0\\.046866601402529504\ \(0\)\
\-\ almost\\:\\ 0\\.04644255277350875\ \(0\)\
\-\ numbness\\:\\ 0\\.046134699130945665\ \(0\)\
\-\ enhances\\:\\ 0\\.0453527520320783\ \(0\)\
\-\ steroids\\:\\ 0\\.04516548177943547\ \(0\)\
\-\ repeat\\:\\ 0\\.04516548177943547\ \(0\)\
\-\ left\\:\\ 0\\.042971023338108524\ \(0\)\
\-\ infarct\\:\\ 0\\.042602673068766535\ \(0\)\
\-\ facial\\:\\ 0\\.041748898833059545\ \(0\)\
\-\ cerebellar\\:\\ 0\\.0414114574049823\ \(0\)\
\-\ resolution\\:\\ 0\\.0414114574049823\ \(0\)\
\-\ csf\\:\\ 0\\.04009544215512373\ \(0\)\
\-\ infarction\\:\\ 0\\.03924166791941674\ \(0\)\
\-\ sided\\:\\ 0\\.03550029902411961\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.03521380565384018\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03448668801602635\ \(0\)\
\-\ effect\\:\\ 0\\.03399503655133983\ \(0\)\
\-\ complete\\:\\ 0\\.033790740831303984\ \(0\)\
\-\ new\\:\\ 0\\.033458291874163576\ \(0\)\
\-\ cerebral\\:\\ 0\\.03326344384004574\ \(0\)\
\-\ now\\:\\ 0\\.03282152347979379\ \(0\)\
\-\ elevated\\:\\ 0\\.03257658832987711\ \(0\)\
\-\ positive\\:\\ 0\\.03115601786836086\ \(0\)\
\-\ revealed\\:\\ 0\\.030814313369281945\ \(0\)\
\-\ t1\\:\\ 0\\.03043253411487914\ \(0\)\
\-\ onset\\:\\ 0\\.030308103662080334\ \(0\)\
\-\ enhancing\\:\\ 0\\.03011183744814336\ \(0\)\
\-\ only\\:\\ 0\\.028869793915561073\ \(0\)\
\-\ lymphoma\\:\\ 0\\.027440434094263885\ \(0\)\
\-\ weeks\\:\\ 0\\.027250311875293802\ \(0\)\
\-\ t2\\:\\ 0\\.027175154705060135\ \(0\)\
\-\ low\\:\\ 0\\.026698517447937074\ \(0\)\
\-\ \\:\\:\\ 0\\.025399434067205955\ \(0\)\
\-\ metastatic\\:\\ 0\\.02416976857995607\ \(0\)\
\-\ acute\\:\\ 0\\.023706509315803318\ \(0\)\
\-\ man\\:\\ 0\\.022707099360561787\ \(0\)\
\-\ mri\\:\\ 0\\.02205927926870359\ \(0\)\
\-\ 2\\:\\ 0\\.02067533142146681\ \(0\)\
\-\ \\-\\:\\ 0\\.020581218637172622\ \(0\)\
\-\ multiple\\:\\ 0\\.020222539364935604\ \(0\)\
\-\ after\\:\\ 0\\.01986518205178879\ \(0\)\
\-\ presents\\:\\ 0\\.01961398084840366\ \(0\)\
\-\ treatment\\:\\ 0\\.019433898422481877\ \(0\)\
\-\ has\\:\\ 0\\.01803033674712672\ \(0\)\
\-\ which\\:\\ 0\\.017922972890365714\ \(0\)\
\-\ on\\:\\ 0\\.016267213761020857\ \(0\)\
\-\ disease\\:\\ 0\\.015693680238378697\ \(0\)\
\-\ mass\\:\\ 0\\.013353494460084995\ \(0\)\
\-\ history\\:\\ 0\\.01326083750232678\ \(0\)\
\-\ pain\\:\\ 0\\.011725934466637469\ \(0\)\
\-\ year\\:\\ 0\\.010742755834527131\ \(0\)\
\-\ old\\:\\ 0\\.009830725807441062\ \(0\)\
\-\ for\\:\\ 0\\.00819222638924399\ \(0\)\
\-\ and\\:\\ 0\\.004045146196229628\ \(0\)\
\-\ with\\:\\ 0\\.003943960991794036\ \(0\)\
\-\ of\\:\\ 0\\.003927094408920959\ \(0\)\
\-\ \\.\\:\\ 0\\.0019943559605250715\ \(0\)\
\-\ the\\:\\ 0\\.0015533627494789416\ \(0\)\
